906.3500 -4.05 (-0.44%)
NSE Oct 06, 2025 15:31 PM
Volume: 67,670
 

906.35
-0.44%
Motilal Oswal
28 July 2018 ALPMs 1QFY19 revenue increased significantly by ~33% YoY to INR8.6b (in-line), primarily driven by the non-US international and domestic businesses. Gross margin shrank 154bp YoY due to a change in product mix. However, EBITDA margin improved ~190bp YoY to 17.5% (est. of 20.9%), led by a decline in employee expense by ~530bp (as % of sales). This, however, was somewhat offset by higher other expense (+190bp). EBITDA grew ~49% YoY to INR1.5b (est. Higher depreciation and tax rate led to PAT growth of ~36% YoY to INR905m (below est.
Alembic Pharmaceuticals Ltd. has lost -27.07% in the last 1 Year
More from Alembic Pharmaceuticals Ltd.
Recommended